spacer
home > pmps > summer 2018 > the race to market
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Race to Market

The development of a new drug product therapy is a complex process that requires careful planning and meticulous execution. Even with these prerequisites, it can result in long lead times, high costs, and immense risks, with development timelines often exceeding 10 years from discovery to regulatory approval. For combination products, the process of bringing a product to market is complicated further. With growing competition in the market of injectable products, drug delivery systems have become increasingly important for the patient, caregiver, and healthcare professionals in terms of ease of use as well as product differentiation. These factors require pharmaceutical and biotechnology companies to identify a strategy for a drug delivery system early in the drug development phase to effectively and efficiently bring the combination product to market.

As the expert that understands the intricacies of the self-injection process and the complexities of the combination product development timelines, a device developer is often contracted to help companies maximise investments and minimise potential delays to commercial launch. Combining this knowledge and experience with a strong set of in-house capabilities, the development process can often be expedited, ultimately ensuring the successful commercialisation of the combination product in a timely manner.

Of Primary Importance

An auto-injector consists of a drugcontaining primary container and a device containing many moving parts and mechanical forces specifically designed to ensure that the drug product is fully injected within the specified delivery requirements. Both the drug product and device are highly regulated components, and the efforts to deliver the drug safely and effectively is an undertaking that requires close collaboration between the company and the device developer.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Taras Seniuch is Director of Business Development at SHL Group: designer, developer, and manufacturer of advanced drug delivery devices such as auto-injectors and pen injectors. With over 17 years of experience within the pharma and medical device industry, Taras leads the business development efforts for the CMO, SHL Pharma, which provides assembly and secondary packaging solutions for SHL-designed devices for pharma and biotech products.
spacer
Taras Seniuch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Clinical Services Announces New Facility Dedicated to Clinical Trial Returns

Philadelphia, USA – October 15, 2018. Leading international pharmaceutical outsourcing services provider PCI Clinical Services (PCI) has announced the completion of a dedicated Returns Management facility at its Clinical Services Center of Excellence at Bridgend, UK. PCI provides a full service Returns Management service for clients, providing visibility and accountability in returning investigational drug product from investigational sites at the conclusion of a clinical study. Returning and reconciling Investigational Medicinal Product (IMP) on completion of a study is a critical part of a Clinical trial and can require complex reverse logistics. Trial outcomes can be impacted if Returns are not processed efficiently and precisely.
More info >>

White Papers

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology

European Society for Medical Oncology (ESMO)

  The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement